Claflin, S and Campbell, JA and Norman, R and Mason, DF and Kalincik, T and Simpson-Yap, S and Butzkueven, H and Carroll, WM and Palmer, AJ and Blizzard, CL and van der Mei, I and Henson, GJ and Taylor, BV, Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New Zealand, The European Journal of Health Economics Article ePub ahead of print. ISSN 1618-7598 (2022) [Refereed Article]
© The Author(s) 2022.
Background: Health state utilities (HSU) are a health-related quality-of-life (HRQoL) input for cost-utility analyses used for resource allocation decisions, including medication reimbursement. New Zealand (NZ) guidelines recommend the EQ-5D instruments; however, the EQ-5D-5L may not sufficiently capture psychosocial health. We evaluated HRQoL among people with multiple sclerosis (MS) in NZ using the EQ-5D-5L and assessed the instrument's discriminatory sensitivity for a NZ MS cohort.
Methods: Participants were recruited from the NZ MS Prevalence Study. Participants self-completed a 45-min online survey that included the EQ-5D-5L/EQ-VAS. Disability severity was classified using the Expanded Disability Status Scale (EDSS) to categorise participant disability as mild (EDSS: 0-3.5), moderate (EDSS: 4.0-6.0) and severe (EDSS: 6.5-9.5). Anxiety/depression were also measured using the Hospital Anxiety and Depression Score (HADS). In the absence of an EQ-5D-5L NZ tariff, HSUs were derived using an Australian tariff. We evaluated associations between HSUs and participant characteristics with linear regression models.
Results: 254 participants entered the study. Mean age was 55.2 years, 79.5% were female. Mean (SD) EQ-5D-5L HSU was 0.58 (0.33). Mean (SD) HSUs for disability categories were: mild 0.80 +- 0.17, moderate 0.57 +- 0.21 and severe 0.14 +- 0.32. Twelve percent reported HSU = 1.0 (i.e., no problems in any domain). Participants who had never used a disease-modifying therapy reported a lower mean HSU. Multivariable modelling found that the HADS anxiety score was not associated with EQ-5D-5L.
Conclusions: for people with MS in NZ was lower than comparable countries, including Australia. We suggest a comparison with other generic tools that may have improved sensitivity to mental health.
|Item Type:||Refereed Article|
|Keywords:||multiple sclerosis, quality of life, EQ-5D-5L, economic evaluation, health technology assessment, neurology|
|Research Group:||Applied economics|
|Research Field:||Health economics|
|Objective Group:||Evaluation of health and support services|
|Objective Field:||Evaluation of health outcomes|
|UTAS Author:||Claflin, S (Dr Suzi Claflin)|
|UTAS Author:||Campbell, JA (Dr Julie Campbell)|
|UTAS Author:||Simpson-Yap, S (Dr Steve Simpson JR)|
|UTAS Author:||Palmer, AJ (Professor Andrew Palmer)|
|UTAS Author:||Blizzard, CL (Professor Leigh Blizzard)|
|UTAS Author:||van der Mei, I (Professor Ingrid van der Mei)|
|UTAS Author:||Henson, GJ (Mr Glen Henson)|
|UTAS Author:||Taylor, BV (Professor Bruce Taylor)|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page